NumFin

TG Therapeutics, Inc.

Simbol: TGTX

NASDAQ

15.21

USD

Tržna cena danes

  • 143.5668

    Razmerje P/E

  • 9.0558

    Razmerje PEG

  • 2.35B

    Kapaciteta MRK

  • 0.00%

    Donos DIV

TG Therapeutics, Inc. (TGTX) Finančni izkazi

Download
LetniČetrtletno
LinearnoLog
Na grafu so prikazane privzete številke v dinamiki za TG Therapeutics, Inc. (TGTX). Prihodki podjetja prikazujejo povprečje 9.191 M, ki je 5.582 % gowth. Povprečni bruto dobiček za celotno obdobje je 8.364 M, ki je 4.522 %. Povprečno razmerje bruto dobička je 0.420 %. Rast čistega dobička za lanskoletno poslovanje podjetja je -1.062 %, kar je enako -0.973 % % v povprečju v celotni zgodovini podjetja.,

LetniČetrtletno
10Y20Y30Y40Y

Bilanca stanja

Če pogledamo fiskalno pot podjetja TG Therapeutics, Inc., opazimo povprečno rast sredstev. Zanimivo je, da ta stopnja znaša , kar odraža tako visoke kot tudi padce podjetja. Pri primerjavi četrtletja s četrtletjem se ta številka prilagodi na 0. Pogled nazaj v preteklo leto razkrije skupno spremembo sredstev v višini 0.703. Na področju kratkoročnih sredstev TGTX znaša 317.943 v valuti poročanja. Velik del teh sredstev, natančneje 217.508, je v denarju in kratkoročnih naložbah. V tem segmentu se je ob primerjavi s podatki za preteklo leto spremenil za 0.249%. Dolgoročne naložbe podjetja, ki sicer niso v središču njegovega zanimanja, znašajo 1.285, če obstajajo, v valuti poročanja. To pomeni razliko v višini -89.640% glede na zadnje obdobje poročanja, kar odraža strateške premike družbe. Dolgoročni profil podjetja kaže skupni dolgoročni dolg v višini 100.118 v valuti poročanja. Ta številka pomeni medletno spremembo v višini 0.334%. Vrednost za delničarje, kot jo prikazuje celotni lastniški kapital, je ovrednotena z vrednostjo 160.502 v valuti poročanja. Letna sprememba tega vidika je -1.105%. Podrobnejši pregled finančnih podatkov podjetja razkrije dodatne podrobnosti. Neto terjatve so ovrednotene na 51.093, zaloge na 39.82, dobro ime pa na 0.8, če obstaja. Celotna neopredmetena sredstva, če so prisotna, so ovrednotena z vrednostjo 0. Obveznosti in kratkoročni dolgovi so 0.19 oziroma {{short_term_deby}}. Celotni dolg je 110.8, neto dolg pa je 17.86. Druge kratkoročne obveznosti znašajo 13.5 in se dodajo k skupnim obveznostim 169.09. Nazadnje se navedena zaloga vrednoti po vrednosti {{preffered_stock}}, če obstaja.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

balance-sheet.row.cash-and-short-term-investments

731.28217.5174.1350.3
605.4
140.4
68.8
84.8
45
102.4
78.9
45.4
16.5
9.7
0.5
0
0.1
0.6
3
10.8
5.4
7.8
0.1
1.6
2.7
3.5
5.8
8.5
2.3

balance-sheet.row.short-term-investments

328.97124.659.415.9
52
27.8
26.8
28
19.9
22.2
23.1
4.9
0
0
0
0
0
0
0
1
4.5
0.4
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

116.5251.101.4
0
0
0.1
0.1
0.1
0.2
0.1
0
0
0
0.2
0
0
0
0
0
0
0
0
0
0.2
0.3
0.4
0
0

balance-sheet.row.inventory

130.8339.80-23.6
0
0
9.7
7.9
5.6
-16
6.1
-3.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

87.639.56.62.9
1.1
0.6
0.4
0.4
0.2
0.3
0.2
0
0
0.1
0.1
0.2
0.8
0.2
0.3
0.2
0
0
0.1
0
0
0
0.1
0
0

balance-sheet.row.total-current-assets

876.79317.9168.3331
611.7
149.2
79
93.3
50.9
86.9
85.2
42.3
18.5
9.8
0.9
0.3
0.9
0.9
3.3
11
5.5
7.8
0.2
1.6
2.9
3.8
6.3
8.5
2.3

balance-sheet.row.property-plant-equipment-net

33.588.110.811.1
11.8
11.8
2.5
2.7
2.4
0
0
0
0
0
0
0
0
0
0.1
0.1
0.1
0
0.1
0.1
0.2
0.1
0.3
0.3
0.1

balance-sheet.row.goodwill

3.20.80.80.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0
2.8
5.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

3.20.80.80.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
3.6
6.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

5.121.312.435.5
1.3
1.3
1.2
0.6
0.6
25
-22.8
4.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

-3.84000
-1.3
-1.3
-1.2
-0.6
-0.6
0
22.8
0
10.4
-438
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

10.391.41.31.3
1.3
1.3
1.2
0
0.2
0.8
0.7
0.1
-10.4
438
17.8
0.1
0.4
0.1
0.1
0.1
0.1
0
0
0
0.1
0.1
-0.1
0
0

balance-sheet.row.total-non-current-assets

48.4511.625.348.7
13.9
13.9
4.6
4.1
3.9
26.6
1.5
5.8
3.6
6.1
17.8
0.1
0.4
0.1
0.2
0.2
0.2
0
0.1
0.1
0.3
0.2
0.2
0.3
0.1

balance-sheet.row.other-assets

153.62000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

1078.87329.6193.6379.6
625.6
163
83.6
97.4
54.8
113.5
86.7
48.1
22.1
15.9
18.6
0.4
1.2
1
3.4
11.2
5.6
7.8
0.3
1.8
3.2
4
6.5
8.8
2.4

balance-sheet.row.account-payables

198.2538.542-0.5
37
30
36.4
25.9
15.3
9.3
4
4.8
1.1
0.7
0.2
0.2
0.5
1.3
1.4
1.6
1.1
0.5
0.6
0.5
0.8
0.5
0
0
0

balance-sheet.row.short-term-debt

5.981.41.62.4
23.8
1.6
0.1
0.1
0.1
0.2
0.3
0.7
0.7
0.9
2.1
1.3
0.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
-55.8
0
-25.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

129.52100.181.576.6
18.1
39.2
0
0
0
0
0
0.1
2.5
4
16.8
0.7
1.2
0
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

6.760.30.5
0.6
0.8
0.9
1.1
1.2
1.4
1.5
1.7
1.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

-0.23---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

35.2113.59.363
26.5
5.4
2.3
1.8
1.4
0.8
0.7
0.7
0.3
0.1
0.5
0.8
0.9
0.6
0.6
0
0.1
0.4
0
0
1.3
0
0.7
0.4
0.3

balance-sheet.row.total-non-current-liabilities

438.57115.481.877.1
18.7
40
20.7
2.4
2
1.4
1.5
1.7
4.3
4.7
20.7
4.6
4.1
1.3
1.4
1.6
1.1
0.5
0.6
0.5
0.8
0.1
-0.1
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
67
35.9
101.6
80.1
40.1
0
0
0
0
0
-1.3
-1.4
-1.6
-1.1
-0.5
-0.6
-0.5
-0.8
0
0
0
0

balance-sheet.row.capital-lease-obligations

43.179.211.911.3
12.1
11.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

685.71169.1135142.5
106.3
124.4
59.6
97.4
54.8
113.5
86.7
48.1
6.5
6.3
24
7.2
5.6
1.9
1.9
1.7
1.2
1
0.6
0.5
2.1
0.6
0.6
0.4
0.3

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.5
0.5
0.5
0
0
0
0

balance-sheet.row.common-stock

0.60.20.10.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0.3
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0.5
0
0
0

balance-sheet.row.retained-earnings

-6194.45-1514.4-1527-1328.7
-980.6
-701.2
-528.3
-354.9
-236.4
-158.1
-95.2
-39.4
-18.9
-0.9
-61.3
-61.9
-59.3
-55
-43
-33.3
-14
-7.5
-28.3
-26.7
-24.8
-18.8
-16.3
-13.5
-8.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.2
-0.2
0
0.3
0
-0.1
0
0
-0.2
-0.3
-0.2
-0.1

balance-sheet.row.other-total-stockholders-equity

1674.261674.7-0.1-0.1
1499.8
-0.1
552.3
421.8
272.2
259.7
175.2
79.4
34.5
10.2
55.9
55.1
54.8
54.2
44.6
42.8
18.1
14.3
27.5
27.4
24.8
21.9
22.5
22.1
10.6

balance-sheet.row.total-stockholders-equity

-4519.58160.5-1527-1328.7
519.4
-701.2
24
67
35.9
101.6
80.1
40.1
15.6
9.6
-5.4
-6.8
-4.4
-0.9
1.5
9.5
4.5
6.8
-0.3
1.2
0.5
3.4
5.9
8.4
2.1

balance-sheet.row.total-liabilities-and-stockholders-equity

-3833.87329.6-1392-1186.2
625.6
-576.8
83.6
97.4
54.8
113.5
86.7
48.1
22.1
15.9
18.6
0.4
1.2
1
3.4
11.2
5.6
7.8
0.3
1.8
3.2
4
6.5
8.8
2.4

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.6
0
0
0
0

balance-sheet.row.total-equity

-4519.58160.5-1527-1328.7
519.4
-701.2
24
67
35.9
101.6
80.1
40.1
15.6
9.6
-5.4
-6.8
-4.4
-0.9
1.5
9.5
4.5
6.8
-0.3
1.2
1.1
3.4
5.9
8.4
2.1

balance-sheet.row.total-liabilities-and-total-equity

-3833.87---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

330.25125.971.851.4
52
27.8
26.8
28
19.9
47.2
23.1
4.9
0
0
0
0
0
0
0
1
4.5
0.4
0
0
0
0
0
0
0

balance-sheet.row.total-debt

144.74110.883.179
42
40.8
0.1
0.1
0.1
0.2
0.3
0.7
3.2
4.9
18.8
1.9
1.3
0
0
0
0
0
0.8
0
0
0
0
0
0

balance-sheet.row.net-debt

-335.8317.9-19.2-219.8
-511.5
-71.8
-41.9
-56.6
-25
-54.8
-55.4
-39.7
-13.3
-4.9
18.3
1.9
1.2
-0.6
-3
-9.8
-0.9
-7.4
0.7
-1.6
-2.7
-3.5
-5.8
-8.5
-2.3

Izkaz denarnih tokov

V zadnjem obdobju se je v finančnem okolju TG Therapeutics, Inc. opazno spremenil prosti denarni tok, ki se je spremenil v 0.822. Podjetje je nedavno povečalo svoj osnovni kapital z izdajo 47.83, kar kaže na razliko 3.425 v primerjavi s prejšnjim letom. Zanimivo je, da je del delnic podjetja, natančneje 0, odkupilo podjetje samo. To dejanje je povzročilo spremembo v 0.000 v primerjavi s prejšnjim letom. Medtem pa obveznosti podjetja trenutno znašajo 0.19 v valuti poročanja. Družba je pri naložbenju porabila neto denarna sredstva v višini -50651000.000 v valuti poročanja. To je premik za 1.531 v primerjavi s prejšnjim letom. V istem obdobju je družba zabeležila 0.42, 0 in -24.88, ki so pomembne za razumevanje naložbenih in odplačilnih strategij podjetja. Družba je pri financiranju porabila 0.000, pri čemer je razlika v primerjavi z letom prej znašala 0.000. Poleg tega je podjetje namenilo 0 za izplačilo dividend svojim delničarjem. Hkrati je izvajalo tudi druge finančne manevre, imenovane 49.75, ki so prav tako pomembno vplivali na denarni tok v tem obdobju. Te sestavine skupaj tvorijo celovito sliko finančnega stanja podjetja in strateškega pristopa k upravljanju denarnih tokov.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

cash-flows.row.net-income

12.6712.7-198.3-348.1
-279.4
-172.9
-173.5
-118.5
-78.3
-62.9
-55.8
-20.5
-26.2
-0.9
0.6
-2.8
-4.3
-12
-9.7
-19.1
-5.9
-6
-1.5
-1.7
-5.8
-2.4
-2.8
-5.2
-3.6

cash-flows.row.depreciation-and-amortization

0.420.40.50.5
0.4
0.3
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0.1
0.1
0.1
0.2
0
0.1
0.1
0.1
0.2
0.1
0

cash-flows.row.deferred-income-tax

-9.28-126.600.5
0
-0.3
-0.1
0.1
5836.8
5836.8
10
10
0.3
0
0.4
0.5
0.3
-1.7
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

37.9337.919.261.3
80.3
11.3
12.9
15.9
7.5
15.7
21.1
5.2
3.4
0.1
0.2
0.4
0.5
1.7
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-84.66-84.7-1.6-12.2
-19.8
25.2
27.8
8.6
8.8
2.1
-6
4.1
0.7
0.4
0.2
-0.2
-1
0
0.2
1
0.1
-0.1
0.1
-2
1.7
-0.1
-0.1
0.1
-0.6

cash-flows.row.account-receivables

-51.09-51.11.4-1.4
0
0
0
0
0
0
0
0
0
0
-0.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-36.94-36.90-16
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

-7.330.2-1116
11.6
-4.8
0
0
6.5
5.5
-0.6
4
0.6
0
0
-0.3
-0.7
-0.2
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

10.73.28-10.8
-31.4
30
27.8
8.6
2.3
-3.4
-5.4
0
0.1
0.4
0.4
0.1
-0.2
0.2
0.2
1
0.1
-0.1
0.1
-2
1.7
-0.1
-0.1
0.1
-0.6

cash-flows.row.other-non-cash-items

11.5128.84.12.4
4
3.5
3.9
0.1
-5836.5
-5836.3
-4.4
-9.6
16.6
0.3
-3.4
1.1
0.1
1.8
1.7
11.8
-0.1
2.5
0
-0.8
2.9
0.1
0.1
0.9
0.2

cash-flows.row.net-cash-provided-by-operating-activities

-31.41000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

000-0.4
-0.4
-0.1
-0.1
0
-0.3
0
0
0
0
0
0
0
0
0
0
0
-0.1
0
0
-0.1
-0.2
-0.1
-0.2
-0.2
-0.1

cash-flows.row.acquisitions-net

0020-0.1
24.2
0.6
0
0
0
0
0
0
0
0
0.5
0
0
-1
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-146.88-146.9-107.3-55.5
-67.4
-29.8
-31.2
-28
-15.2
-49
-18.3
-4.9
0
0
0
0
0
1
0
0
-5
0
0
0
-0.1
0
0
0
0

cash-flows.row.sales-maturities-of-investments

96.2396.287.355.6
43.3
29.3
32.5
19.8
42.1
24.4
0
0
0
0
0
0
0
0
1
3.5
0.9
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

-50.650-200.1
-24.2
-0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.2
0
3
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-50.65-50.7-20-0.3
-24.5
-0.7
1.2
-8.2
26.5
-24.7
-18.4
-4.9
0
0
0.5
0
0
0
1
3.5
-4.2
0.2
0
2.9
-0.3
-0.1
-0.2
-0.2
-0.1

cash-flows.row.debt-repayment

-24.88-24.9-1-30
0
-29.2
0
0
0
0
-0.7
0
-0.2
0
0
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

47.4147.80.62.2
679.7
175
113.6
131.5
4.4
67.8
65.6
37.6
0
9.8
2.2
0
0
7.9
0
12.4
3.4
9.8
0
1.9
1.2
0
0.1
10.6
1.5

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
-0.6
-0.5
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

97.2249.8-0.469.2
0.1
58.4
0
2.1
0.6
1
3.7
2.3
12.2
0
-0.2
1
3.9
0
0
-0.7
0
-0.8
0
-0.8
0
0
0
0
-0.2

cash-flows.row.net-cash-used-provided-by-financing-activities

72.772.7-0.441.4
679.8
204.2
113.6
133.7
5
68.7
68.6
39.8
11.9
9.8
1.9
1
3.9
7.9
0
11.7
3.4
9
0
0.5
0.7
0
0.1
10.6
1.3

cash-flows.row.effect-of-forex-changes-on-cash

0-66.900
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-9.36-9.4-196.6-254.5
440.8
70.7
-14.1
31.7
-30
-0.7
15.2
24
6.7
9.7
0.5
-0.1
-0.5
-2.4
-6.8
8.9
-6.5
5.7
-1.5
-1.1
-0.8
-2.3
-2.7
6.3
-2.8

cash-flows.row.cash-at-end-of-period

406.1592.9103.6300.2
554.7
113.9
43.2
56.7
25
55.1
55.7
40.5
16.5
9.7
0.5
0
0.1
0.6
3
9.8
0.9
7.4
0.1
1.6
2.7
3.5
5.8
8.6
2.2

cash-flows.row.cash-at-beginning-of-period

415.51102.3300.2554.7
113.9
43.2
57.3
25
55.1
55.7
40.5
16.5
9.7
0
0
0.1
0.6
3
9.8
0.9
7.4
1.7
1.6
2.7
3.5
5.8
8.5
2.3
5

cash-flows.row.operating-cash-flow

-31.41-31.4-176.2-295.6
-214.5
-132.8
-128.9
-93.8
-61.6
-44.7
-35.1
-10.8
-5.2
-0.1
-2
-1
-4.4
-10.2
-7.8
-6.2
-5.7
-3.5
-1.4
-4.5
-1.2
-2.3
-2.6
-4.1
-4

cash-flows.row.capital-expenditure

000-0.4
-0.4
-0.1
-0.1
0
-0.3
0
0
0
0
0
0
0
0
0
0
0
-0.1
0
0
-0.1
-0.2
-0.1
-0.2
-0.2
-0.1

cash-flows.row.free-cash-flow

-31.41-31.4-176.2-296
-214.9
-132.9
-129
-93.8
-61.9
-44.7
-35.1
-10.8
-5.2
-0.1
-2
-1
-4.5
-10.2
-7.8
-6.3
-5.8
-3.5
-1.4
-4.6
-1.3
-2.4
-2.8
-4.3
-4.1

Vrstica izkaza poslovnega izida

Prihodki TG Therapeutics, Inc. so se v primerjavi s prejšnjim obdobjem spremenili za 82.900%. Bruto dobiček podjetja TGTX znaša 219.11. Odhodki iz poslovanja podjetja so 198.47 in so se v primerjavi s prejšnjim letom spremenili za 1.595%. Odhodki za amortizacijo znašajo 0.42, kar je -0.910% sprememba glede na zadnje obračunsko obdobje. Stroški poslovanja so sporočeni v višini 198.47, ki kaže 1.595% spremembo glede na preteklo leto. Stroški prodaje in trženja znašajo 0, kar pomeni 0.000% spremembo v primerjavi s preteklim letom. EBITDA na podlagi zadnjih podatkov znaša 0 in predstavlja 1.107% rast v primerjavi s preteklim letom. Prihodki iz poslovanja so 20.63, ki kažejo -1.107% spremembo v primerjavi s preteklim letom. Sprememba čistih prihodkov je -1.062%. Čisti prihodki v zadnjem letu so znašali 12.67.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

income-statement-row.row.total-revenue

233.66233.72.86.7
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0
0
0
0
0
0
0
0
0
0
0.5
2.7
5.4
1.2
3
0.1
0.1

income-statement-row.row.cost-of-revenue

14.2214.60.30.8
0.4
0.3
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2.1
4.1
0.8
-0.2
-0.1
0

income-statement-row.row.gross-profit

219.44219.12.55.9
-0.2
-0.1
0.1
0.1
0.1
0.2
0.2
0.2
0
0
0
0
0
0
0
0
0
0
0.5
0.6
1.3
0.4
3.2
0.2
0.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

66.03---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

135.72---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

-12.12---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

11.3754.72.3
0.5
1.5
0.1
-0.1
0.4
1
0.8
3.4
1.9
0
0
0
0
0
10
11.9
0
1.2
0
0
0.1
0.1
0.2
0.1
0

income-statement-row.row.operating-expenses

198.81198.5195.4350.7
273.7
169.2
174.6
118.9
79.1
63.3
55.9
20.3
25.8
0.9
2
1.8
4.4
12.1
10
19.4
6.1
4.8
2.1
3.7
4.5
3.1
5.9
5.5
3.9

income-statement-row.row.cost-and-expenses

213.03213195.6351.5
273.7
169.2
174.6
118.9
79.1
63.3
55.9
20.3
25.8
0.9
2
1.8
4.4
12.1
10
19.4
6.1
4.8
2.1
5.8
8.5
3.9
5.7
5.4
3.9

income-statement-row.row.interest-income

10.18010.25.6
6.3
5.3
0.9
0.3
0.3
0.2
0.1
0
0
0
0.5
0.6
0.5
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

12.6212.610.25.6
6.3
5.3
0
0
0
1
0.9
1
0.9
0
1.3
0.5
0.1
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

-12.12---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-3.94-7.6-5.5-3.3
-5.8
-3.8
0.1
-0.1
0.4
1
0.8
0.6
0.8
0
3.4
-1.1
-0.3
0.1
0
0
0.1
-2.5
0
1.3
-2.7
0
0
0.2
0.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

11.3754.72.3
0.5
1.5
0.1
-0.1
0.4
1
0.8
3.4
1.9
0
0
0
0
0
10
11.9
0
1.2
0
0
0.1
0.1
0.2
0.1
0

income-statement-row.row.total-operating-expenses

-3.94-7.6-5.5-3.3
-5.8
-3.8
0.1
-0.1
0.4
1
0.8
0.6
0.8
0
3.4
-1.1
-0.3
0.1
0
0
0.1
-2.5
0
1.3
-2.7
0
0
0.2
0.2

income-statement-row.row.interest-expense

12.6212.610.25.6
6.3
5.3
0
0
0
1
0.9
1
0.9
0
1.3
0.5
0.1
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

1.510.44.72.3
0.5
1.5
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0.1
0.1
0.1
0.2
0
0.1
0.1
0.1
0.2
0.1
0.2

income-statement-row.row.ebitda-caps

22.02---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

20.6320.6-192.8-344.8
-273.6
-169.1
-174.4
-118.7
-79
-63.2
-55.7
-23
-26.9
-0.9
-2
-1.8
-4.4
-12.1
-10
-19.4
-6.1
-4.8
-1.6
-3.1
-3.2
-2.7
-2.7
-5.3
-3.8

income-statement-row.row.income-before-tax

13.0613.1-198.3-348.1
-279.4
-172.9
-173.5
-118.5
-78.3
-62.9
-55.8
-20.5
-25.9
-0.9
1.3
-2.8
-4.7
-12
-10
-19.4
-6.1
-7.2
-1.6
-1.8
-5.9
0
0
-5.1
-3.6

income-statement-row.row.income-tax-expense

3.290.45.57.5
6.5
6.5
-0.9
-0.2
-0.7
-0.2
0.1
-2.5
0.3
0
-2.6
1
-0.1
-0.1
-0.3
-0.2
-0.2
1.2
0
-1.4
2.6
-0.3
0.1
-0.1
-0.2

income-statement-row.row.net-income

13.2812.7-203.8-355.6
-285.9
-179.3
-173.5
-118.5
-78.3
-62.9
-55.8
-20.5
-18.1
-0.9
0.6
-2.8
-4.3
-12
-9.7
-19.1
-5.9
-6
-1.5
-1.7
-5.8
-2.4
-2.8
-5.2
-3.6
Podobne delnice
Morda vas zanima tudi:
SRNE
Sorrento Therapeutics, Inc..
0.0145 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
7.85 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.0361 USD
NASDAQ
T5O.DE
CytoTools AG.
0.488 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.06 NOK
OSL
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ
SPHRF
Starpharma Holdings Limited.
0.0774 USD
PNK

Pogosto zastavljeno vprašanje

Kaj je TG Therapeutics, Inc. (TGTX) skupna sredstva?

TG Therapeutics, Inc. (TGTX) skupna sredstva so 329587000.000.

Kakšen je letni prihodek podjetja?

Letni prihodki so 209786000.000.

Kolikšna je stopnja dobička podjetja?

Dobiček podjetja je 0.939.

Kakšen je prosti denarni tok podjetja?

Prosti denarni tok je -0.220.

Kolikšna je neto stopnja dobička podjetja?

Čista stopnja dobička je 0.057.

Kolikšni so skupni prihodki podjetja?

Celotni prihodki so 0.088.

Kaj je TG Therapeutics, Inc. (TGTX) čisti dobiček (čisti dobiček)?

Čisti dobiček (čisti prihodek) je 12672000.000.

Kolikšen je skupni dolg podjetja?

Skupni dolg je 110795000.000.

Kolikšni so stroški poslovanja?

Stroški poslovanja so 198475000.000.

Kolikšno je število denarnih sredstev podjetja?

Denarna sredstva podjetja so 92933000.000.